Drug · CHEMBL13
Comparisons in its trials42
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 42
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 1-NEB vs 2-MET: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 150 of 252 | 51 of 84 | 336 | NCT00142584 | Trial comparisons |
| 1-NEB vs 2-MET: deaths from any cause | 3 of 252 | 0 of 84 | 336 | NCT00142584 | Trial comparisons |
| 1-NEB vs 2-MET: serious adverse events | 11 of 252 | 2 of 84 | 336 | NCT00142584 | Trial comparisons |
| Active Comparator vs Experimental: serious adverse events | 1 of 139 | 3 of 112 | 251 | NCT01213173 | Trial comparisons |
| Arm 1 - Active Comparator vs Arm 2 - Experimental: The Proportion of Patients With Resting Heart Rate Controlled to ≤60bpm Between Groups | 25 of 116 | 28 of 115 | 231 | NCT01213173 | Trial comparisons |
| Arm 1 - Active Comparator vs Arm 2 - Experimental: The Proportion of Patients With Resting Heart Rate Controlled to ≤60bpm Between Groups | 28 of 116 | 46 of 115 | 231 | NCT01213173 | Trial comparisons |
| Treatment vs Control: Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism | 10 of 103 | 2 of 95 | 198 | NCT01837069 | Trial comparisons |
| Treatment vs Control: deaths from any cause | 0 of 103 | 0 of 95 | 198 | NCT01837069 | Trial comparisons |
| Treatment vs Control: serious adverse events | 0 of 103 | 0 of 95 | 198 | NCT01837069 | Trial comparisons |
| Remifentanil vs Tramadol + Metoprolol: Number of Participants With Postoperative Nausea and Vomiting | 14 of 44 | 10 of 44 | 88 | NCT02484859 | Trial comparisons |
| Remifentanil vs Tramadol + Metoprolol: serious adverse events | 21 of 44 | 0 of 44 | 88 | NCT02484859 | Trial comparisons |
| Black Participants vs White Participants: deaths from any cause | 0 of 40 | 0 of 40 | 80 | NCT03070184 | Trial comparisons |
| Black Participants vs White Participants: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT03070184 | Trial comparisons |
| Nebivolol vs Metoprolol: serious adverse events | 0 of 34 | 0 of 36 | 70 | NCT00829296 | Trial comparisons |
| Tesofensine/Metoprolol vs Placebo: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT02737891 | Trial comparisons |
| Tesofensine/Metoprolol vs Placebo: serious adverse events | 0 of 30 | 1 of 30 | 60 | NCT02737891 | Trial comparisons |
| Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing vs Arm B: Pyronaridine-artesunate 60-day Redosing: deaths from any cause | 0 of 26 | 0 of 30 | 56 | NCT01523002 | Trial comparisons |
| Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing vs Arm B: Pyronaridine-artesunate 60-day Redosing: serious adverse events | 0 of 26 | 2 of 30 | 56 | NCT01523002 | Trial comparisons |
| Metoprolol Study Group vs Diltiazem Study Group: serious adverse events | 0 of 29 | 0 of 25 | 54 | NCT01914926 | Trial comparisons |
| Nebivolol vs Metoprolol Extended-Release (ER): deaths from any cause | 0 of 25 | 0 of 26 | 51 | NCT00547300 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL13/comparisons